Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102356 | 0.95 | MGLL (0.58) | MGLLTRPV1LTA4HPTGS1EPHX2 | |
| SCHEMBL101957 | 0.95 | MGLL (0.58) | MGLLTRPV1LTA4HPTGS1EPHX2 | |
| SCHEMBL101952 | 0.95 | MGLL (0.58) | MGLLTRPV1LTA4HPTGS1EPHX2 | |
| SCHEMBL102685 | 0.95 | MGLL (0.58) | MGLLTRPV1LTA4HPTGS1EPHX2 | |
| SCHEMBL102358 | 0.95 | MGLL (0.58) | MGLLTRPV1LTA4HPTGS1EPHX2 | |
| SCHEMBL102366 | 0.88 | PTGS1 (0.54) | TRPV1LTA4HPTGS1EPHX2 | |
| SCHEMBL102357 | 0.87 | PTGS1 (0.51) | TRPV1PTGS1L3MBTL1 | |
| SCHEMBL102688 | 0.85 | PTGS1 (0.49) | TRPV1LTA4HPTGS1MTNR1AMTNR1B | |
| SCHEMBL19363887 | 0.84 | MGLL (0.46) | MGLLEPHX2HDAC3HDAC2L3MBTL1 | |
| SCHEMBL101827 | 0.84 | LTA4H (0.47) | MGLLTRPV1LTA4HPTGS1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | claimed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | claimed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | FAAH, FAAH2, TRPV1 | MGLL 915/4885TRPV1 3/4885LTA4H 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.